

(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences
Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

"CODE OF ETHICS IN RESEARCH AND PUBLICATIONS"

Research is the avenue of Progress

Index

SI. No	Title	Page No.
1.	Introduction	2
2.	Preamble	2
3.	Principles and ethics in research	2-3
4.	Research practice	4
5.	Collaborations and Contributions	5
6.	Authorship , Publications and Conflicts of interest	5 -7
7.	Plagiarism	7
8.	Assessment and Review	8
9.	Training new Researchers	8
10.	References	9







(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences
Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

Introduction

This Code of Ethics in Research sets forth general principles of ethical conduct to guide scholars toward the highest ideals of scientific research. Research is the foundation of knowledge that brings new energy, builds state of the art facilities, promotes research publications, develops collaborations and becomes part of active community that shares the mission objectives. The principles represent aspirational goals and delineate enforceable standards that should direct researchers to an ethical course of action.

1. Preamble

We, the faculty and research staff of M R Ambedkar Dental College and Hospital, hold that our profession as researchers entails an unqualified commitment to the pursuit of truth, an abiding dedication to the promotion of the public good, and a sustained interest in mentoring students and fellow researchers.

Alongside our efforts to maintain the ideals of scholarly integrity and academic freedom, we accept our duty to uphold human dignity and life in all its manifestations promote the interests of the greater community which this University seeks to serve and develop. Cognizant of our responsibility to our public, we hereby bind ourselves to the strictest measure of integrity and the highest ethical standards to be worthy of the public's trust.

2. Principles and Ethics in Research

Research protocols of all the students and faculty undergoes extensive review by Ethics committee and review board before approval for the studies.

PRINCIPAL

R. Ambedkar Dental College & Hosp

P.R.P.



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

All the proposed and presented research protocols should follow scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.

- 2.1 The design of each experimental procedure involving human subjects is clearly formulated in an experimental protocol and reviewed by research committee.
- 2.2 Every research project involving human participants is preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or others. The right of the research participant to safeguard his or her integrity is always respected.
- 2.3 Every precaution should is taken to respect the privacy of the participant and to minimize the impact of the study on the his/her physical and mental integrity and on his or her personality.
- 2.4 The accuracy of research results is preserved.
- 2.5 In any research on human beings, each potential research participant is adequately informed of the aim, methods, anticipated benefits and potential hazards of the study and the discomfort it may entail.
- 2.6 Informed consent is obtained from all human participants of our experiments or studies. That is, participants are free to decide on their involvement only after we have provided them with information that is relevant to that decision.
- 2.7 Maintain the autonomy of participants, especially students and subordinates, by refraining from offering inducements that may serve to coerce them into participating.
- 2.8 Safeguard the rights and welfare of persons and communities whose status and vulnerabilities may impair autonomous decision-making.



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

3. Research Practice:

- 3.1 Transparency, Openness and responsibility in the conduct and presentation of research is maintained by keeping detailed and complete records of our research undertaking.
- 3.2Transparency in the use and disbursement of resources for our research and also declaring promptly any conflict of interest in our engagement in research and presentation of research results.
- 3.3 Respect the confidentiality of sources by not using or releasing data and information revealed to us in confidence.
- 3.4Ensure the accuracy of all data that we and our collaborators have gathered and/or used in our research. Ensure that only the correct data, information, and research results shall be reported in journals, conferences, and reports to clients in case of commissioned research
- 3.5 Take reasonable steps to rectify significant errors that we or others have found in our published data, via the issuance of erratum, retraction, or correction of the data.
- 3.6 Avoid misleading statements or declarations and vague assertions that could be subject to misinterpretation. If such misinterpretation is brought to our attention, it is our obligation to immediately issue a clarification or rectification. Avoid making exaggerated claims that are not warranted by the results of our research inquiry.

PRINCIPAL
M.R. Ambedkar Dental College & Hospital
Bengaluru - 560 005

4



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

4. Collaborations and Contributions:

Render unto our peers, colleagues, students, and research participants the respect that they deserve.

- 4.1 To provide assistance to other researchers, especially if we are uniquely qualified to do so by our expertise.
- 4.2 Respect the confidentiality and proprietary rights of our peers, colleagues, and students whose material we review for publication, presentation, or funding by a grant.
- 4.3 Take diligent care of equipment, material resources, and results.
- 4.4 Grant authorship in accordance with the significance of collaborators' contribution in the research.
- 4.5 Appropriately attribute and credit to others their accomplishments and research results which we may have utilized in our own research
- 4.6 Acknowledge the material contribution of others in our research undertaking.

5. Authorship, Publications and conflict of interest:



- 5.1 Researcher should publish the results and interpretations of his or her research in an honest, transparent and accurate manner, so that other researchers could elaborate on the findings or replicate them.
- 5.2 Authorship must be based solely on substantial intellectual contribution to the research. This includes: significant contribution in initiating scientific idea, formulating conceptions, designing research, significant share in data acquisition, in



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences
Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

the analysis and interpretations of data and in drafting the article or revising it critically for intellectual content.

- 5.3. Acquisition of funding, provision of technical assistance or materials, the collection of data, general supervision of the research group, by themselves, do not justify authorship. All authors are fully responsible for the content of the publication, unless it is specified they are responsible only for a specific part of the study within their speciality. When listing authors and their affiliations, it is appropriate to mention what was the nature of their contribution to the research.
- 5.4. Sequence of authors should be consistent with the existing customs in a given scientific discipline and agreed by all, ideally at the start of the project.
- 5.5. Intellectual contributions of others that have influenced the reported research should be appropriately acknowledged.
- 5.6. Grant and limit authorship to those who made a significant contribution to the research endeavour
- 5.7. Financial or other types of support for research should be properly mentioned and acknowledged.
- 5.8. Publication of the same (or substantial parts of the same) work in different journals is acceptable only with the consent of the editors of the journals and where proper reference is made to the first publication.
- 5.9. Eliminating conflict of interest by avoiding non-professional relationships between the evaluator and the evaluated, be that individual or institution or by



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences
Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

avoiding a connection between a member of the fund granting authority and a person or research unit to which these funds are granted.

5.10 Authors should select a journal that is relevant to the scope of their research and is likely to be interested in publishing their work. Authors should also ensure that the journal is reputable and has a high impact factor. Authors should follow the journal'sguidelines for formatting the manuscript. The manuscript should be written in clear and concise language, with correct spelling and grammar. Publication of the same (or substantial parts of the same) work in different journals is acceptable only with the consent of the editors of the journals and where proper reference is made to the first publication.

6. Plagiarism:

- 6.1.1 Not to plagiarize; that is, to present portions of another's report or data as our own, even if the other work or data source is cited occasionally.
- 6.1.2 Clearly citing all sources of information and data that we use which are not the results of our own research.
- **6.1.3** Give proper acknowledgment and credit to resource/funding sources of our research.
- **6.1.4** All the scientific presentations, protocols and manuscripts of the faculty and the students should undergo suitable plagiarism check and the ones with the plagiarism report less than 10% will only be considered.

P.R.P.



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

7. Assessment and Review

Reviewers involved in the assessment and review process with regard to research projects, publications, scientific achievements, applications for faculty positions in scientific institutions and other forms of recognition, should withdraw from involvement in the review process, if there is any conflict of interests between them and evaluated individuals.

The process of peer review should provide accurate, objective, substantiated and justifiable assessments. Reviewers should maintain confidentiality until the manuscript is published. e. Reviewers and editors shall not make any use of the data or ideas presented in submitted manuscripts without the author's permission.

8. Training new researchers:

The institution faculty are authorised to conduct certain types of studies are entrusted special care of undergraduate and postgraduate students. These staff to supervise research of students and guarantee reliable supervision by exercising control over the number of students per supervisor. The supervisor to perform his or her duties reliably, in particular to his or her best to ensure that research conducted under his or her supervision meets all the requirements of scientific work and that dissertation is free from unacknowledged borrowings from other authors. The supervisor should ensure that his or her research student is familiar with ethical values in conducting research, and above all, should be a role model for his or her student.

PRINCIPAL

M.R. Ambedkar Dental College & Hospital

Bengaluru - 560 005



(Founded by : Ananda Social & Educational Trust)
ISO 9001:2015 CERTIFIED

Affiliated to Rajiv Gandhi University of Health Sciences Recognised by Dental Council of India

1/36, Cline Road, Cooke Town, Bengaluru - 560 005 Ph: 080 - 2546 0747 www.mradc.in

References:

- Ethical principles expressed in the Declaration of Helsinki (Adopted by the 18thWorldMedical Assembly, Helsinki, Finland, June 1964, and amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975; 35th World Medical Assembly, Venice, Italy, October 1983; 41st World Medical Assembly, Hong Kong, September 1989; 48th World Medical Assembly, Somerset West, Republic of South Africa, October 1996; and the 52nd World Medical Assembly, Edinburgh, Scotland, October 2000; Note of Clarification on Paragraph 29 added by the World Medical Assembly, Washington 2002; Note of Clarification on Paragraph 30 added by the World Medical Assembly, Tokyo 2004, 59th WMA general Assembly, Seoul, October 2008)
- International Ethical Guidelines for e.g. The Nuremburg Code (1945), the Council of International Organizations of Medical Sciences (CIOMS), the Belmont Report 1979, the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva 2002), and the European Convention on Human Rights and Biomedicine 1977
- The IEC establishes its own Standard Operating Procedures based on the ICMR guidelines (2006), Schedule Y (Drugs and Cosmetics Act 1940, amendment 20th Jan 2005), Operational Guidelines for Ethics Committees that Review Biomedical Research (WHO 2000), and ICH GCP, 1996 and the local regulations, CFR 45 (US FDA).
- Good Manners in Science. A Set of Principles and Guidelines drawn up by the Committee for Ethics in Science of the Polish Academy of Sciences (2001).



1/36, Cline Road, Cooke Town, Bengaluru-560005.

STANDARD OPERATING PROCEDURES (SOP) OF INSTITUTIONAL ETHICS **COMMITTEE (IEC)**

FOR

BIOMEDICAL AND HEALTH RESEARCH

M R AMBEDKAR DENTAL COLLEGE AND HOSPITAL

No.1/36, Cline Road, Cooke Town, Bangalore-560005

Title: Working Procedures

Section A – SOP Guidelines for IEC Members

SOP Version 2.0 Dated 01 October 2023

Contact: Dr. Tarulatha R Shvagali

Member Secretary

M R AMBEDKAR DENTAL COLLEGE AND **HOSPITAL**(MRADC)

Mobile No.: +91-7742129768 Email: drtarulatha@gmail.com

Prepared by: Reviewed by: Approved by: Dr. Fouzia T Dr. Tarulatha R Shyagal Dr. Nagaraj B M Member – IEC Chair Person-IEC **Member Secretary – IEC**



1/36, Cline Road, Cooke Town, Bengaluru-560005.

TABLE OF CONTENTS

Sl. No.	Subject	Pg No.
		3
1	Adoption of SOP	3
2	Objective	3
3	Authority under which MRADC-IEC is constituted	3
4	Terms of Reference for IEC	3
5	Role and responsibilities of MRADC-IEC	5
6	Composition of MRADC-IEC	5
7	Membership requirements	7
8	Quorum requirements	12
9	Independent consultants	12
10	Terms of Appointment, Resignation, Termination/Disqualification,	13
	Replacement	
11	Training of Ethics Committee Members	14
12	Confidentiality & Conflict of Interest	14
13	Conduct of MRADC-IEC Meetings	15
14	Application Procedures	15
15	Application	16
16	Review procedures	16
17	Aspects considered during review of research proposal Exemption and	20
	Exceptions	
18	Decision-making	23
19	Communicating the decision	23
20	Follow up procedures for approved proposals by PI/Guide	24
21	Adverse Events	25
22	Record keeping and archiving at the office of MRADC-IEC	26
23	Inspection and Audits	27
24	Special consideration/protection of vulnerable population	27
25	List of Abbreviations	28
26	Appendix – 1 Research proposal Submission – DHR form	29



1/36, Cline Road, Cooke Town, Bengaluru-560005.

SHORT TITLE:

The following are called as "Standard Operating Procedures for the Institutional Ethics Committee (IEC) for Biomedical and Health Research of M R Ambedkar Dental College and Hospital (MRADC), Bangalore."

I. ADOPTION OF SOP:

M R Ambedkar Dental College and Hospital , Bangalore, herein after referred to as "MRADC" has adopted these written Standard Operating Procedures (SOP) for discussion and approval of institutional/collaborative research projects to safeguard dignity, right, safety and well-being of all research participants and to ensure that the research is carried under prescribed guidelines.

II. OBJECTIVE:

The objective of these Standard Operating Procedures of the Institutional Ethics Committee (IEC) for Biomedical and Health Research of M R Ambedkar Dental College and Hospital , Bangalore is to maintain effective functioning of the IEC-MRADC and to ensure quality and technical excellence and consistent ethical review of all the submitted health and biomedical research proposals and on-going approved research studies involving human participants in accordance with the ICH-GCP, New CT rules March 2019 and ICMR ethical guidelines 2017 for biomedical research on human subjects.

III. AUTHORITY UNDER WHICH MRADC-IEC IS CONSTITUTED:

The Head of the institute, M R Ambedkar Dental College and Hospital will appoint the Chairperson and all the committee members based on their competence, experience and integrity, for which an official request letter will be sent. Members will confirm their acceptance to the Head of the institute by providing all the required information for membership.

IV. TERMS OF REFERENCE FOR IEC ARE AS FOLLOWS

- 1. Ensure the highest scientific and ethical standards of research.
- 2. Review and approve, proposals for clinical, basic or translational research projects (Intra and Extra mural) for scientific and ethical content
- 3. Improve ethical standards and issue guidelines on ethical dilemmas related to patient care services

P.R.P.



- 4. To function as a forum to advise the administration in case of any ethical issues that may arise from patients, families or public
- 5. To maintain leadership as a national standard of reference in all fields
- 6. To issue and periodically, update and revise SOPs and guidelines for effective functioning of IEC as and when necessary
- 7. Continuing education in clinical research, bioethics and ethical aspects of clinical practice by conducting seminars, workshops and interactive discussions for all categories of staff members including nursing and paramedical
- 8. To initiate and commission research studies on ethical aspects of practice.

The committee does not address or interfere in matters of administration, nor does the committee function as a grievance cell for staff members.

V. ROLES AND RESPONSIBILITIES OF MRADC-IEC:

The MRADC-IEC will review all types of research proposals involving human participants with a view to safeguard the dignity, rights, safety and well-being of allactual and potential research participants before approving the research proposals. The goals of research, however important, will never be permitted to override the health and well-being of the research subjects.

The MRADC-IEC will ascertain whether all the cardinal principles of research ethics viz., Autonomy, Beneficence, Non-maleficence, Respect for Free and informed Consent, Respect for Human Dignity, Respect for Vulnerable Persons, Respect for Privacy and Confidentiality and Justice are taken care of in planning, conducting and reporting of the proposed research. For this purpose, it will look into the aspects of protocol review, selection of participants, voluntary participation of potential participants, informed consent process, risk benefit ratio, distribution of burden and benefit, maintenance of privacy and confidentiality and provisions for appropriate compensations. It will review the proposals before the commencement of the study as well as review periodically until the completion of the study through appropriate well documented procedures. Such a review may be based on the periodic study progress reports furnished by the investigators/Guides.

The mandate of the IEC shall be to review all clinical study/research projects to be conducted at the Institution involving human beings directly or indirectly, irrespective of the funding agency. MRADC-IEC will provide advice to the researchers on all aspects of

P.R.P.



the welfare and safety of the research participants after ensuring the scientific soundness of the proposed research through appropriate Scientific Review by Research Committee. In case an ethics committee revokes its approval accorded to a study protocol, it will record the reasons for doing so and at once communicate such a decision to the investigator.

In case of Serious Adverse Event (SAE) such as death or disability occurring to the clinical study subject, the ethics committee shall forward its report on the serious adverse event of death or disability, after due analysis, along with its opinion on the financial compensation, if any.

- i. The basic responsibility of an EC is to ensure protection of the dignity, rights, safety and well-being of the research participants.
- ii. The EC must ensure ethical conduct of research by the investigator team.
- iii. The EC is responsible for declaration of conflicts of interest to the Chairperson, if any, at each meeting and ensuring these are recorded in the minutes.
- iv. The EC should perform its function through competent initial and continuing review of all scientific, ethical, medical and social aspects of research proposals received by it in an objective, timely and independent manner by attending meetings, participation in discussion and deliberations.
- v. TheECmustensurethatuniversalethicalvaluesandinternationalscientificstanda rds are followed in terms of local community values and customs.
- vi. The EC should assist in the development and education of the research community in the given institute (including researchers, clinicians, students and others), responsive to local health care requirements.
- vii. Responsibilities of members should be clearly defined (details in Table4.1). The SOPs should be given to EC members at the time of their appointment.
- viii. TheSecretariatshouldsupporttheMemberSecretaryandAlternateMemberSecretary (if applicable) in all their functions and should be trained in documentation and filing procedures under confidentiality agreement.
 - $ix. \ \ The EC should ensure that privacy of the individual and confidentiality of data in clumbers of the confidence of the confidence$

P.R.P.



ding the documents of EC meetings is protected.

- x. The EC reviews progress reports, final reports and AE/SAE and gives needful suggestion regarding care of the participants and risk minimization procedures, if applicable.
- xi. The EC should recommend appropriate compensation for research related injury, wherever required.
- xii. The EC should carry out monitoring visits at study sites as and when needed.
- xiii. The EC should participate in continuing education activities in research ethics and get updated on relevant guidelines and regulations.
- xiv. The EC may see that conduct of same/similar research by different investigators from same institution is harmonized. "Me too" research (replicative) should not to be encouraged and submission of same research to different funding agencies should not be accepted.

VI. COMPOSITION OF MRADC-IEC:

MRADC-IEC will be multidisciplinary and multi-sectorial body in composition and independent. The number of members of the Institutional Ethics Committee [IEC] is maintained between 7 and 15.

The chairperson of the IEC will be from outside the Institution to maintain the independence of the Committee. The Member Secretary will belong to the same Institution and will conduct the proceedings of the committee. Other members will be a mix of medical/non-medical, legal, scientific and non-scientific persons and may also include members of public to reflect different points of view. There will be representation of age and gender in the committee to safeguard the interest and welfare of all sections of the society. Member will be aware of local, social and cultural norms, as an important social control mechanism. IEC may invite subject experts to take their views, whenever it is needed.

P.R.P.



1/36, Cline Road, Cooke Town, Bengaluru-560005.

VII. Membership requirements

The members of MRADC-IEC will include

- 1. Chairperson
- 2. Member Secretary
- 3. Basic medical scientist/s area (including preferably a Pharmacologist)
- 4. Clinicians
- 5. legal experts
- 6. Social Scientist/ philosopher/ ethicist/ theologian
- 7. Lay person/s from the community

A Sub-Board of the main IEC may review proposals submitted by undergraduate or postgraduate students or if necessary, an IEC may be separately constituted for the purpose, which will review proposals in the same manner as described above.

- i. ECs should be multi-disciplinary and multi-sectoral.
- ii. There should be adequate representation of age and gender.
- iii. Preferably 50% of themembers should be non-affiliated or from outside the institution.
- iv. The number of members in an EC should preferably be between seven and 15 and a minimum of five members should be present to meet the quorum requirements.
- v. The EC should have a balance between medical and non-medical members/technical and non-technical members, depending upon the needs of the institution.



II. The composition, affiliations, qualifications, member specific roles and responsibilities are as below

Composition, affiliations, qualifications, member specific roles and responsibilities of an EC

S. No	Members of EC	Definition/description
1 .	Chairperson/ Vice Chairperson (optional) Non-affiliated Qualifications - A well-respected person fromany background with prior experience of having served/ serving in an EC	 Conduct EC meetings and be accountable for independent and efficient functioning of the committee Ensure active participation of all members(particularly non-affiliated, non-medical/ non- technical) in all discussions and deliberations Ratify minutes of the previous meetings In case of anticipated absence of both Chairperson and Vice Chairperson at a planned meeting, the Chairperson should nominate a committee member as Acting Chairperson or the members present may elect an Acting Chairperson on the day of the meeting. The Acting Chairperson should be
		 anon-affiliated person and will have all the powers of the Chairperson for that meeting. Seek COI declaration from members and ensure quorum and fair decision making. Handle complaints against researchers, EC members, conflict of interest issues and requests for use of EC data, etc.



_		,
2	Member Secretary/ Alternate	Organize an effective and efficient procedure
	Member Secretary (optional)	for receiving, preparing, circulating and
	Affiliated	maintaining each proposal for review • Schedule EC meetings, prepare the agenda and
	 Qualifications - Should be a staff member of the institution Should have knowledge and experience in clinical research and ethics, be motivated and have good communication skills 	 minutes Organize EC documentation, communication and archiving Ensure training of EC secretariat and EC members Ensure SOPs are updated as and when required Ensure adherence of EC functioning to the SOPs Prepare for and respond to audits and inspections Ensure completeness of documentation at the time of receipt and timely inclusion in agenda for EC review. Assess the need for expedited review/exemption from review or full review.
	• Should be able to devote	• Assess the need to obtain prior scientific
	adequate time to this activity	review, invite independent consultant, patient
	which should be protected by the	or community representatives.
	institution	Ensure quorum during the meeting and record discussions and decisions.
3	Basic Medical Scientist(s) Affiliated/ non-affiliated Qualifications -	• Scientific and ethical review with special emphasis on the intervention, benefit-risk
	 Non-medical or medical person with qualifications in basic medical sciences In case of EC reviewing clinical trials with drugs, the basic medical scientist should preferably be pharmacologist 	 analysis, research design, methodology and statistics, continuing review process, SAE, protocol deviation, progress and completion report For clinical trials, pharmacologist to reviewthe drug safety and pharmacodynamics.



4 .	Clinician(s) Affiliated/ non-affiliated Qualifications - • Should be individual/s with recognized medical qualification, expertise and training	 Scientific review of protocols including review of the intervention, benefit-risk analysis, research design, methodology, sample size, site of study and statistics Ongoing review of the protocol (SAE, protocol deviation or violation, progress and completion report) Review medical care, facility and appropriateness of the principal investigator, provision for medical car, management and compensation. Thorough review of protocol, investigators brochure (if applicable)and all other protocol details and submitted documents.
6	Legal expert/s Affiliated/ non-affiliated Qualifications- • Should have a basic degree in Law from a recognized university, with experience • Desirable: Training in medical law. Social scientist/ philosopher/ ethicist/theologian Affiliated/ non-affiliated Qualifications - • Should be an individual with social/ behavioral science/ philosophy/religious qualification and training and/or expertise and be sensitive to local cultural and moral values. Can be from an NGO involved in health-related activities	 Ethical review of the proposal, ICD along with translations, MoU, Clinical Trial Agreement (CTA), regulatory approval, insurance document, other site approvals, researcher"s undertaking, protocol specific other permissions, such as, stem cell committee for stem cell research, HMSC for international collaboration, compliance with guidelines etc. Interpret and inform EC members about new regulations if any Ethical review of the proposal, ICD along with the translations. Assess impact on community involvement, socio—cultural context, religious or philosophical context, if any Serve as a patient/participant/ societal / community representative and bring in ethical and societal concerns.



7 | Lay person(s)

- . Non- affiliated Qualifications
 - Literate person from the public or community
 - Has not pursued a medical science/ health- related career in the last 5 years
 - May be a representative of the community from which the participants are to be drawn
 - Is aware of the local language, cultural and moral values of the community
 - Desirable: involved in social and community welfare activities

- Ethical review of the proposal, ICD along with translation(s).
- Evaluate benefits and risks from the participant"s perspective and opine whether benefits justify the risks.
- Serve as a patient/participant/ community representative and bring in ethical and societal concerns.
- Assess on societal aspects if any.

The quorum should be as below

*Medical members are clinicians with appropriate medical qualifications. Technical members are persons with qualifications related to particular branch in which the study is conducted, for example social sciences.



Member Secretary belongs to the institute and conducts the business of the Committee. When member secretary is on leave, documents will be acknowledged by alternateMember Secretary of Institutional Ethics Committee. Chairperson is not affiliated to the Institute. Ethics Committee members are selected and appointed based on their personal capacity and on Ethical/Scientific knowledge and expertise, Experience, Interest & Commitment. Members are appointed for a period of 3 years.

XIII. QUORUM REQUIREMENTS:

Requirement of the members is 7 to 15, and it is ensured that we have at least 5members for the meeting to meet the requirements of the quorum and in which at least one member will be from outside the institution, and one member will be a non-scientific member and one from opposite gender. All decisions will be taken in meetings. Quorum will have 5 members with the following representation.

- a) A minimum of five members present in the meeting room.
- b) The quorum should include both medical, non medical or technical or/and non-technical members.*
- c) Minimum one non-affiliated member should be part of the quorum.
- d) Preferably the lay person should be part of the quorum.
- e) The quorum for reviewing regulatory clinical trials should be in accordance with current CDSCO requirements.

No decision is valid without fulfilment of the quorum

IX: INDEPENDENT CONSULTANTS:

The MRADC-IEC may call upon subject experts as independent consultants to provide special review of selected research protocols, if need be. These experts may be specialists in ethical or legal aspects, specific diseases or methodologies, or represent specific communities, patient groups or special interest groups. Eg. Cancer patients, HIV/ AIDS positive persons or ethnic minorities. They will be required to give their specialized views but will not take part in the decision making process which will be made by the members of the MRADC-IEC.

P.R.P.



X. TERMS OF APPOINTMENT, RESIGNATION, TERMINATION/ DISQUALIFICATION AND REPLACEMENT 1.Appointment:

All members are appointed by Head of the institute of Institute of Nephro Urology, and in Consultation with chairman and member secretary, IEC. Member Secretary belongs to the institute and conducts the business of the Committee. When member secretary is on leave, documents will be acknowledged by alternate Member Secretary of Institutional Ethics Committee

- 1. All members will serve for a period of 2 to 3 years on renewable basis. New members will be included in the IEC in such a way that there will be a mix of recently appointed members and members with experience.
- 2. During the term, MRADC Head of the institute in consultation with the Chairman can disqualify any member if the contribution is not adequate and/or there is a long period of (member) non availability.
- 3. A member can tender resignation of membership from the IEC to the MemberSecretary with information to MRADC Head of the institute through the Chairperson after serving one month advance notice.
- 4. MRADC Head of the institute can replace the member of IEC as and when required.
- 5. Conflict of interest is to be declared by members of the MRADC IEC prior to review meeting.

2. Resignation:

Any member can resign from the committee with a prior notice of 1 month.

3. Termination/Disqualification:

A member may be disqualified/terminated by the Chairperson in case of:

- Conduct unbecoming for a member
- Relocation to faraway place.
- Absence for 4 consecutive meetings without any valid reason and without prior permission of the chairman.

P.R.P.



1/36, Cline Road, Cooke Town, Bengaluru-560005.

4. Replacement:

New member will be appointed by Head of the institute of Institute of Nephro Urology, having requisite qualification and experience in place of a member who has resigned/terminated/upon death.

XI: TRAINING OF ETHICS COMMITTEE MEMBERS: (NEW & EXISTING)

All members are provided with:

- 1. IEC SOP, Indian-GCP, ICH-GCP (E6) Guidelines,(CDSCO),NDCT rules 2019 March 2019, and ICMR Guidelines one hard copy will be available for reference (with year of publication) at the IEC office M R Ambedkar Dental College and Hospital.
- 2. All members are informed about their role in protocol review.
- 3. All members are contMRADCously updated with the latest amendments/modifications in above mentioned guidelines.

All are motivated to attend various conferences/workshops on bioethics.

References:

- Good Clinical Practice (GCP), as per Government of India, Drugs and Cosmetics Act and rules there under, Rule 122-DAA, Amendments 1, 2 and 3 in 2013 and Schedule Y as Amended on 20th January 2005.
- ICMR Guidelines for Biomedical Research on Human Subjects (2017)
- Operational Guidelines for Ethics Committees that review Biomedical Research, WHO, 2000.
- NDCT rules 2019 released by CDSCO office

XII. CONFIDENTIALITY AND CONFLICT OF INTEREST AGREEMENT:

A set of conditions in which professional judgment concerning a primary interest like patients welfare orthe validity of research tends to be unduly influenced by a secondary interest like non-financial (person, academics or political) or financial gain is termed as Conflict of Interest(COI).

There should be no conflict of interest. The members shall voluntarily withdraw from the Institutional Ethics Committee meeting, while making a decision, which evokes conflict of interest and is indicated in writing to Chairperson prior to the reviews and is recorded in the minutes.

P.R.P.



All members of the EC are given an undertaking on confidentially, not to disclose or utilize, directly or indirectly, any Confidential or Proprietary information belonging to a third party in fulfilling this agreement and Conflict of Interest which is signed by every member and copy of it is maintained in records.

XIII. CONDUCT OF MRADC-IEC MEETINGS:

The Chairperson will conduct all meetings of the MRADC-IEC. In the absence of the chairperson an alternate Chairperson [Dy. Chairperson] or a member elected by the members present, who will conduct the proceedings of the EC meeting. The Member Secretary is responsible for organizing the meetings, maintaining the records and communicating with all concerned. He/She will prepare the minutes of the meetings and get it approved by the Chairperson and all the members. Virtual Meetings may be conducted in case of inability of core committee member to be present physically with justification being recorded.

XIV. APPLICATION PROCEDURE:

- 1. All proposals will be submitted on any working day at least **3 weeks in advance** of scheduled meeting in the DHR prescribed application form, the details of which are given depending on type of study such as academic/investigator initiated/clinical trial. Copy of SOP of MRADC-IEC will be given to PI/Co-investigators (Co-PI)/Guide if he/she has applied for review for the first time will who in turn bring it to the notice of investigating team.
- 2. All relevant documents will be enclosed with application form by PI as per DHR checklist and guidelines for PI (Section B), Documents will be made available with office of Member Secretary MRADC-IEC.
- 3. Required number of copies of the proposal along with the application and documents in prescribed format duly signed by the (PI) and/Collaborators/Research Scholars is submitted to the office of IEC of M R Ambedkar Dental College and Hospital and the same will be acknowledged.
- 4. Every application will be allotted an IEC registration number to be used for all future correspondence and reference. The date of MRADC-IEC meeting will be intimated to

P.R.P.



the PI to attend the meeting and to make a brief presentation using power point slides of the proposal and to clarify the points raised by the members.

- 5. The decision of the committee on the proposal will be communicated in writing. If revision is to be made, the revised document in required number of copies will be submitted within a stipulated period of time as specified in the communication on/or before the next meeting.
- 6. All research proposals/ clinical studies involving human subjects funded/sponsored etc., will be charged an administrative fee/processing fee/as specified by the Research Secretariat/Office of IEC of MRADC. Waiver of these fees is permissible for non-funded studies, academic studies and studies funded by organizations like ICMR, UGC, DST Government of India, State Science & Technology Department, UNICEF,WHO, USAID, Non Profitable Organizations etc. In general, waiver of administrativefee will beat the discretion of MRADC-IEC, total approximately15% need to be paid as institutional service charges for maintenance.
- 7. Applicants are required to mention specific ethical issues separately in their application to be approved by IEC.

XV. APPLICATION:

All clinical research proposals (5 hard copies and 1 soft copy) shall be submitted along with the information and documents as specified in the required format by Biomedical and Health Research (Section B for PIs Annexture - 1).

XVI. REVIEW PROCEDURES:

- The meeting of the MRADC-IEC will be held at periodic intervals or on quarterly basis.
 Additional review meetings can also be held with short notice as and when required.
 Meetings will be scheduled in accordance with the need of the work load. Virtual meeting will be conducted if felt necessary for expedited review
- 2. The IEC"s member-secretary/secretariat shall screen the proposals for their completeness and depending on the risk involved categorize them into three types, namely -a] exemption from review b] expedited review and c] full review (explanation is given below).
- 3. Decisions will be taken by consensus after discussion and voting.

P.R.P.

PRINCIPAL



- 4. Investigators/researchers may be invited to offer clarifications if need be. The PI will present the proposal in person in the IEC meeting. When the PI is not available due to unavoidable reasons the Co PI will present the proposal.
- 5. Independent consultants/subject experts may be invited to offer their opinion on specific research proposals if needed.

a) **EXEMPTION FROM REVIEW**:

Proposals which present less than minimal risk fall under this category as indicated in following situations.

1. Research on educational practices such as instructional strategies or effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.

Exceptions:

- When clinical study/research on use of educational tests, survey or interview
 procedures, or observation of public behaviour can identify the human participant
 directly or through identifiers, and the disclosure of information outside research
 could subject the participant to the risk of civil or criminal or financial liability or
 psychosocial harm.
- 2. When interviews involve direct approach or access to private papers.

S. No.	Types of review		
No. 1	Exempti on from review	Proposals with less than minimal risk where there are no linked identifiers, for example; • research conducted on data available in the public domain for systematic reviews or meta-analysis; • observation of public behavior when information is recorded without any linked identifiers and disclosure would not harm the interests of the observed person;	
		 quality control and quality assurance audits in the institution; comparisonofinstructionaltechniques, curricula, or class roommanagement methods; consumer acceptance studies related to taste and food quality; and 	

P.R.P.

PRINCIPAL



	• public health programmes by Govt agencies such as programe evaluation where the sole purpose of the exercise is refinement and improvement of the programe or monitoring (where there are no individual identifiers).
2 Expedit	Proposalsthatposenomorethanminimalriskmayundergoexpeditedreview, for
ed	example;
review	 research involving non-identifiable specimen and human tissue from sources like blood banks, tissue banks and left-over clinical samples; researchinvolvingclinicaldocumentationmaterialsthatarenon-identifiable (data, documents, records); modification or amendment to an approved protocol including administrative changes or correction of typographical errors and change in researcher(s); revised proposals previously approved through expedited review, full review or continuing review of approved proposals; minor deviations from originally approved research causing no risk or minimal risk; progress/annual reports where there is no additional risk, for example activitylimitedtodataanalysis.ExpeditedreviewofSAEs/unexpectedAEs will be conducted by SAE subcommittee; and for multicenter research where a designated main EC among the participating sites has reviewed and approved the study, a local EC may conduct only an expedited review for site specific requirements in addition to the full committee common review. researchduringemergenciesanddisasters(SeeSection12forfurtherdetails).



3	Full	Allresearchproposalspresentingmorethanminimalriskthatarenotcovere
	committ	d under exempt or expedited review should be subjected to full
	ee	committee review, some examples are;
	review	• research involving vulnerable populations, even if the risk is minimal;
		• research with minor increase over minimal risk (see Table 2.1 for further details);
		• studies involving deception of participants (see section 5.11 for further details);
		• research proposals that have received exemption from review, or have undergone expedited review/undergone subcommittee review
		should be ratified by the full committee, which has the right to
		reverse/or modify any decision taken by the subcommittee or
		expedited committee;
		• amendments of proposals/related documents (including but not limited
		to informed consent documents, investigator"s brochure,
		advertisements, recruitment methods, etc.) involving an altered risk;major deviations and violations in the protocol;
		 any new information that emerges during the course of the research
		for deciding whether or not to terminate the study in viewof the
		altered benefit-risk assessment;
		• research during emergencies and disasters either through an expedited
		review/ scheduled or unscheduled full committee meetings. This
		may be decided by Member Secretary depending on the urgency and
		need;
		• priorapprovalofresearchonpredictableemergenciesordisastersbefore the actual crisis occurs for implementation later when the actual
		emergency or disaster occurs.



XVIII ASPECTS CONSIDERED DURING REVIEW OF RESEARCH PROPOSAL

1	Social values	• The basic requirement for health research to be ethically permissible is that it must have anticipated social value. The outcome of the research should be relevant to the health problems of society. All stakeholders, including sponsors, researchers and ECs must ensure that the planned research has social value.
2	Scientific design and conduct of the study	 Valid scientific methods are essential to make the research Ethically viable as poor science can expose research participants or communities to risks without any possibility benefit. Although ECs may obtain documentation from a prior
		scientific review, they should also determine that the research methods are scientifically sound, and should examine the ethical implications of the chosen research design or strategy. • The EC can raise scientific concerns (even if the study has prior approval of a scientific committee) if it may affect quality of research and or safety of research participants.
3	Benefit-risk assessment	 The benefits accruing from the planned research either to the participants or to the community or society in general must justify the risks inherent in the research. Risks may be physical, psychological, economic, social or legal and harm may occur either at an individual level or at the family, community or societal level. It is necessary to first look at the intervention under investigation and assessits potential harm and benefits and then consider the aggregate of harm and benefits of the study as a whole. The EC should review plans for risk management, including withdrawal criteria with rescue medication or procedures. The EC should give advice regarding minimization of risk/discomfort wherever applicable.

P.R.P.



		• Adequate provisions must be made for monitoring and auditing the conduct of the research, including the constitution of a Data and Safety Monitoring Board(DSMB)if applicable (for example in clinical trials)
4	Selection of the study population and recruitment of research participants	 Recruitment should be voluntary and non-coercive. Participants should be fairly selected as per inclusion and exclusion criteria. However, selection of participants should be distributive such that a particular population or tribe or economic group is not coerced to participate or benefit. Participants should be able to opt out at any time withouttheir routine care being affected. No individual or group of persons must bear the burden of participation in research without accruing any direct or indirect benefits. Vulnerable groups may be recruited after proper justification Is provided.
5	Payment for participat ion	 Plans for payment for participation, reimbursement toincurred costs, such as travel or lost wages, incidental expenses and other inconveniences should be reviewed. There is a need to determine that payments are not so large as to encourage prospective participants to participate in the research without due consideration of the risks or against heir better judgment. No undue inducement must be offered.
6	Protection of research participants' privacy and confidentiality	 ECs should examine the processes that are put in place to safeguard participants" privacy and confidentiality. Researcher cords to be filed separately than routine clinical records such as in a hospital setting.



	1	
7	Community	• The EC should ensure that due respect is given to the
	consideratio	community, their interests are protected and the research
	n	addresses the community"s needs.
		The proposed research should not lead to any stigma or
		discrimination. Harm, if any, should be minimized.
		• Plans for communication of results to the community at the
		end of the study should be carefully reviewed.
		• It is important to examine how the benefit soft here search will be disseminated to the community.
8	Qualifications of	• The EC should look at the suitability of qualifications and
	researchers and	experience of the PI to conduct the proposed research along
	adequacy	with adequacy of site facilities for participants.
	assessment of studysites	
9	Disclosure or	• The EC should review any declaration of COI by a
	declaration of	researcher and suggest ways to manage these.
	potential COI	The EC should manage COI within the EC and
	potential COI	members
		with COI should leave the room at the time of decision
		making in a particular study.
10	Plans for medical	The proposed plan for tackling any medical injuries or
	management and	emergencies should be reviewed.
	compensation for	Source and means for compensation for study related injury
	study	should be ascertained.
	related injury	
11	Review of the	The informed consent process must be reviewed keeping in
11		
	informed consent	mind the following:
	process	The process used for obtaining informed consent, including
		the identification of those responsible for obtaining consent
		and the procedures adopted for vulnerable populations;
		The adequacy, completeness and understand ability of the
		information to be given to the research participants, and
		when
		appropriate, their LARs;

P.R.P.



• contents of the patient/participation information sheet
including the local language translations (See section 5 for
further details);
• back translations of the informed consent documenting English, wherever required;
• provision for audio-visual recording of consent process, if
applicable, as per relevant regulations; and
• if consent waiver or verbal/oral consent request has been
asked for, this should be reviewed by assessing whether the
protocol meets the criteria. See section 5 for further details.

XVIII. DECISION-MAKING:

- 1. Members will discuss the various issues before arriving at a consensus decision. When consensus is not arrived at, the decision will be made by voting procedure.
- 2. A member will withdraw from the meeting during the decision procedure concerning an application where a conflict of interest arises and this will be indicated to the chairperson prior to the review of the application and recorded in the minutes.
- 3. Decision will be made only in meetings where quorum is complete.
- 4. Only members can make the decision. The expert consultants when present will only offer their opinions.
- 5. Decision may be to approve, reject or revise the proposals. Specific suggestions for modifications and reasons for modifications and reasons for rejection will be given.
- 6. In cases of conditional decisions, clear suggestions for revision and the procedure for having the application revised will be specified.
- 7. Modified proposals will be reviewed by an expedited review through identified members.
- 8. Procedures for appeal by the investigators/researchers will be clearly defined.

XIX.COMMUNICATING THE DECISION

1. Decision of the meeting on the proposals will be communicated by the Member Secretary in writing to the PI/Research Scholar within 14 working days after the meeting and approval letter will be sent to the applicant within 2 weeks. All the

P.R.P.



approvals will be valid for two years or for the duration of the project whichever is less. Investigator has to get his or her project re-approved after two years if necessary.

- 2. The communication of the decision will include:
 - a. Name and address of IEC.
 - b. The date, place and time of decision.
 - c. The name and designation of the PI/Guide
 - d. Title of the research proposal reviewed.
 - e. Along with protocol, other documents reviewed- clear description of these documents along with Version No. and Date.
 - f. A clear statement of decision reached and follow up procedure with submission of progress reports.
 - g. Any advice by the IEC to the applicant including the schedule/plan of on-going review by the MRADC-IEC.
 - h. In case of conditional decision, any requirement by IEC, including suggestions for revision, and the procedure for having the application re-reviewed are informed.
 - i. In case of rejection of the proposal, reason(s) for the rejection will be clearly stated.
 - j. Signature of the member secretary with date and seal.

XX.FOLLOW UP PROCEDURES FOR APPROVED PROPOSALS BY PI/GUIDE:

- 1. IEC will review the progress of all the studies for which decision has been reached from the time of decision till the completion/termination of the research.
- 2. Progress of all the research proposals is a responsibility of PI/Guide to be submitted to IEC Office at a regular interval once in six months. But in special situations, IEC will conduct the follow up review at shorter intervals based on the need, nature and events of research project.
- 3. Periodic status report of study will be submitted at prescribed intervals in the prescribed format for review based on the safety concerns and this prescribed interval will be specified in the Letter of Communication of Decision to the PI from the IEC office.
- 4. Final report will be submitted at the end of study.
- 5. Following instances and events will require the follow-up review/ Renewed Approval:
 - a. Any protocol amendment likely to affect rights, safety or well-being of research subject of for conduct of study.

P.R.P.



- b. Serious or unexpected ADR related to study or product, action taken by Investigator/Guide
- c. Any event or information that may affect the benefit/risk ratio of the study.
- 6. Protocol deviation, if any, will be informed with adequate justifications.
- 7. Any new information related to the study will be communicated.
- 8. Premature termination of study shall be notified with reasons along with summary of the data obtained so far.
- 9. Change of study title/guide/investigators/sites must be informed to the office of IEC.
- 10. Monitoring over site mechanism will be in place to monitor the approved studies. Actual site visits can be made especially in the event of reporting of adverse events or violations of human rights and appropriate action will be taken when required and communicated to the applicant indicating modification/suspension/termination/continuation of the project.
- 11. Applicant must inform the time of completion of study and send the result summary to IEC. IEC must receive a copy of final brief summary of study completed from the applicant in the required format.

XXI.ADVERSE EVENTS:

- 1. All serious adverse events (SAEs) shall be reported to the IEC within 24 hours from the time of its occurrence.
- 2. All SAEs reported will be reviewed by the EC for their integrity and will give their opinion on compensation to the study subject.

SAE report should contain the following:

- a. Project details Title, PI name
- b. Patient details Age, Gender Initials and other relevant details.
- c. Suspected drug/s
- d. Indication for which the drug was prescribed or tested
- e. Dosage form and strength
- f. Route of administration
- g. Therapy dates
- h. Details of Concomitant drugs (Including non-prescription/ OTC drugs)
- i. Full description of the event with body site and severity, sign and symptoms
- j. Start date and time of onset of event
- k. Stop date and time or duration of event
- 1. Information of sequel, results of specific tests, treatment that have been done for outcome of event

P.R.P.

PRINCIPAL

M.R. Ambedkar Dental College & Hospital
Bengaluru - 560 005

~ 25 ~



- m. Any relevant information of the event
- n. Clinical investigator details name, address, telephone number, profession
- o. De-challenge and re-challenge information
- p. Causality assessment
- q. Information on recovery or sequel, results of specific tests and/or treatment that may have been conducted for a fatal outcome, cause of death and a comment on its possible relationship to the suspected reaction, any post- mortem details
- r. Anything relevant to facility assessment of the case, such as medical history including allergy, drug or alcohol abuse, family history, findings for special investigations.
- s. Date of reporting the event to Licensing Authority
- t. Date of reporting of event to Ethics Committee
- u. Outcome of the event
- v. Any other information for analysis
- w. Signature of the Investigator
- x. Details of pregnancy

XXII.RECORD KEEPING AND ARCHIVING AT THE OFFICE OF MRADC-IEC:

- 1. All the documents and communications of IEC will be dated, filed and archived in a secure place.
- 2. Only persons, who are authorized by the Chairman of IEC will have the access to the study related documents.
- 3. All the documents related to study/research proposals will be archived for a minimum period of 3 years in the Institute, following the completion/termination of the study.
- 4. PI/Co-I will present the PPT at IEC meeting for formal approval and will share the same as soft copy by email to drtarulatha@gmail.com for circulation to IEC members.
- 5. Following documents will be filed and archived with proper label on the top of filefor easy identification
 - a. Constitution and composition of MRADC-IEC
 - b. Curriculum Vitae (CV) of all members of MRADC-IEC with records of training in Human ethics if any and appointment letters.
 - c. Standard Operating Procedures of MRADC-IEC
 - d. Annual reports
 - e. A record of all income and expenses of the EC, including allowances and reimbursements made to the secretariat and EC members;

P.R.P.



- f. The published guidelines for submission established by the EC.
- g. Copy of all study protocols with enclosed documents, progress reports, and SAEs.
- h. Agendas and Minutes of all IEC meetings duly signed by the Chairperson/Member secretary.
- i. Copy of all existing relevant national and international guidelines on ethics and laws along with amendments.
- j. Copy of all correspondence with members, Principal Investigators and other regulatory bodies.
- k. Record of all notification issued for premature termination of a study with a summary of the reasons;
- 1. Final report of the approved projects, including microfilms, CDs

XXIII .INSPECTION & AUDITS:

- 1. IEC is open to inspection with or without notice by the officers authorized by DHR to verify compliance to requirements of–ICMR, Indian GCP& ICH –GCP guidelines.
- 2. All the IEC related records and communications as required by the authority will be shared by member secretary.
- 3. Concerned authority can visit any parts of the premises and can interview IEC members, study subject and staff if needed.
- 4. Based on inspection reports future Improvement in the functioning of IEC will be implemented so as to achieve the fundamental aim of safeguarding the rights, safety and wellbeing of study/trial subjects.

XXIV. SPECIAL CONSIDERATION/PROTECTIONS OF VULNERABLE POPULATION:

While, all the above requirements are applicable to biomedical research as a whole irrespective of the specialty of research there are certain specific concerns pertaining to specialized areas of research which require additional safe guards /protection and specific considerations for the IEC to take a note of. Examples of such instances are research involving – children, pregnant and lactating women, vulnerable participants and those with diminished autonomy besides issues pertaining to commercialization of research and national/international collaboration. The observations and suggestions of IEC will be given in writing in unambiguous terms in such instances. ICMR Guidelines for Biomedical and Health Research as applicable will be followed for protection of vulnerable population.

P.R.P.



M. R. Ambedkar Dental College & Hospital-IEC,# 1/36, Cline Road, Cooke Town, Bengaluru-560005.

	XXV : LIST OF ABBREVIATIONS
ADR	ADVERSE DRUG REACTION
AE	ADVERSE EVENT
BARC	BHABHA ATOMIC RESEARCH CENTRE
CD	COMPACT DISC
CO-PI	CO-PRINCIPAL INVESTIGATOR
DSMB	DATA SAFETY MONITORING BOARD
DBT	DEPARTMENT OF BIOTECHNOLOGY
DST	DEPARTMENT OF SCIENCE & TECHNOLOGY
DCGI	DRUG CONTROLLER GENERAL OF INDIA
DHR	DEPARTMENT OF HEALTH RESEARCH
EC	ETHICS COMMITTEE
GCP	GOOD CLINICAL PRACTICE
HMSC	HEALTH MINISTRY'S SCREENING COMMITTEE
ICMR	INDIAN COUNCIL OF MEDICAL RESEARCH
IEC	INSTITUTIONAL ETHICS COMMITTEE
ICH	INTERNATIONAL COUNCIL OF HARMONISATION
IND	INVESTIGATIONAL DRUG delete
OPD	OUT PATIENT DEPARTMENT
OTC	OVER THE COUNTER
PIS	PARTICIPANT INFORMATION SHEET
PICF	PARTICIPANT INFORMED CONSENT FORM
PI	PRINCIPAL INVESTIGATOR
SAE	SERIOUS ADVERSE EVENTS
SDC	STATE DRUG CONTROLLER
MRADC	M R AMBEDKAR DENTAL COLLEGE AND HOSPITAL
SOP	STANDARD OPERATING PROCEDURE
UNICEF	UNITED NATIONS CHILDREN'S FUND
	UNITED STATES AGENCY FOR INTERNATIONAL
USAID	DEVELOPMENT
UGC	UNIVERSITY GRANTS COMMISSION

P.R.P.



M. R. Ambedkar Dental College & Hospital-IEC,# 1/36, Cline Road, Cooke Town, Bengaluru-560005.

Appendix 1 - Research proposal Submission - DHR form

P.R.P.

PRINCIPAL

M.R. Ambedkar Dental College & Hospital

Bengaluru - 560 005

Logo of the Institute

Application Form for Initial Review

(Name of the Institution) EC Ref. No. (For office use):

General Instructions : a) Tick one or more options as applicable. Mark NA if not applicable

b) Attach additional sheets if required

SECTION A - BASIC INFORMATION

ADMINISTRATIVE DETAILS	8		
(a) Name of Organization	n:		
(b) Name of Ethics Cor	mmittee:		
(c) Name of Principal Inv	estigator:		
(d) Department/Division:		(e) Date of subm	ission: dd mm yy
(f) Type of review requeste	ed¹:		
Exemption from review	v ☐ Expedited rev	iew 🛘 Full cor	nmittee review \square
(g) Title of the study:			
(h) Protocol number (If	any):	Version	number:
(i) Details of Investigators	:		
Name	Designation and Qualification	Department and Institution	Address for communication ²
Principal Investigator/Gu	iide		
Co-investigator/student	/fellow		
(j) Number of studies when	re applicant is a:		
i) Principal Investigator	at time of submission	ii) Co-Investiga	tor at time of submission:
(k) Duration of the stud	y:		p.P.P.
			PRINCIPAL

2.	FUN	IDING DETAILS	AND BUDGET	-			
	(a)	Total estimate	d budget for	site:			
		At site		In India	Globally		
	(b)	Self-funding \square	Instituti	onal funding \square F	unding agency (Spec	ify) 🗆	
		SI	ECTION	B - RESEARCH R	ELATED INFO	ORMATION	
3.	OVE	ERVIEW OF RES	EARCH				
	(a)	Lay summary	³ (within 300	words):			
	(b)	Type of study:					
		Basic Sciences		Clinical		Cross Sectional	
		Retrospective		Epidemiological/		Case Control	
		Prospective		Public Health		Cohort	
		Qualitative		Socio-behavioural		Systematic Review	
		Quantitative		Biological samples/ Da	ata ∐ □		
		Mixed Method		Any others (Specify)			
4	MET	THODOLOGY					
т.			ımher of narti	cipants (as applicable)			
	(4)				Globally		
					-		
						study, mention the criteria	
		saturation		(7		
						P.R.P.LP	
300				that a person with no prior knowle			

Summarize in the simplest possible way such that a person with no prior knowledge of the subject can easily understand it. The M.R. Ambedkar Dental College & Hospital Bengaluru 小த்திரி 25 0.

	(b)	Is there an external laborate	ory/outsourcing invo	lved for investig	jations? ⁴	Yes ☐ No ☐] NA 🗆
	(c)	How was the scientific quali	ity of the study asses	sed?			
		Independent external review	w 🛘 Review by sp	onsor/Funder	☐ Revi	ew within PI's institution	
		Review within multi-centre research group	☐ No review				
		Date of review:			do	l mm yy	
		Comments of scientific com	nmittee, if any (100 w	vords)			
		SECTION	C: PARTICIPA	NT RELAT	TED INFO	RMATION	
5.	REC	CRUITMENT AND RESEARCH	H PARTICIPANTS				
	(a)	Type of participants in the st	tudy:				
		Healthy volunteers	Patients	Vulnerable pe	ersons/ Speci	al groups \square	
		Others \square (Sp	pecify)				
		Who will do the recruitm	ment?				
		Participant recruitment me	thods used:				
		leaflets/Letters Sc	V/Radio ads/ Docial media/ stitution website	Patients / Fa	mily/ Friends itals	☐ Telephone ☐	
		Others \square (Sp	pecify)				
	(b)	i. Will there be vulnerable	persons / special gr	oups involved ?	,	Yes ☐ No [□ NA □
		ii. If yes, type of vulnerable	e persons / special gr	oups			_
		Children under 18 yrs			-	lactating women	
		Differently abled (Menta	al/Physical)			Students/Nurses/Staff	
		Elderly			Institutionaliz		
		Economically and social	_	⊔ ,	Refugees/Mi	grants/Homeless	Ш
		Terminally ill (stigmatized	d or rare diseases) L				
		Any other (Specify):		<u> </u>			
		iii. Provide justification f	for inclusion/exclus	ion			
							iv.
		Are there any additional safe					
						P.P.P.	
						PRINCIPAL	
					AAR Amb	adkar Dental Callege &	Hospital

	If yes,	Monetary \square						Is there any reimbursement to the participants?									
			Non-monetary		Provide	details											
(d)	Are there any incentives to the participants? If yes, Monetary Non-monetary Provide details							Yes 🗆	Yes □ No □								
(a)			t room it mont food / in					the DI / Ineti	*tion?								
(e)		Monetary	t recruitment fees/ ind Non-monetary			e details	ovided to	ine Pi / insu	Yes 🔲	No 🗖							
S. BEI	NEFITS A	AND RISKS															
(a)		there any anticipa	ted physical/social/ps evel of risk ⁵ :	sycholo	ogical disc	omforts	risk to pa	articipants?	Yes 🗆	No 🗖							
		s than Minimal risk			Minima	l risk											
	Mino	or increase over mi	nimal risk or low risk		More th	nan mini	mal risk o	r high risk									
	ii. Des	cribe the risk mar	nagement strategy:														
(b)	 What ar	re the potential be	nefits from the study?	,	Yes	No	If yes,	Direct	Indirect								
	For the	participant															
	For the	society/communi	ty														
	For imp	provement in scien	ce														
	Please	describe how t	he benefits justify	the ris	sks												
(c)	Are adv	erse events expect	ed in the study ⁶ ?					Yes	□ No □ N	Α□							
	-	orting procedures a	and management stra	_					Yes 🗆	No 🗆							
		-	consent? If yes, pleas	-	-		-		Yes □	 No 🗖							
⁵ For ca	tegories of		hical Guidelines for Biomedi														

(b)	Version number a	and date of	Participant Information	n She	eet (PIS):				
		Version number a	and date of	Informed Consent Fo	rm (l	CF):				
(c	:)	Type of consent p	lanned for							
		Signed consent		Verbal/Oral consent		Witnessed consent		Audio-Video consent	(AV)	
		Consent from LAR (If so, specify from	n whom)	For children<7 yrs parental/LAR consent		Verbal assent from minor (7-12 yrs) along with parental consent		Written asserminor (13-18 with parental	yrs) alon	
		Other								
		(specify)								
(d	l)	Who will obtain the	e informed	consent?						
			lurse/Couns			☐ Other ☐ (Specif				
(e	.)	-		(PIS) and Informed C						
(5	,	English	Local lang	` _		「				
			•							
(f))	Provide details of	consent red	quirements for previous	sly sto	ored samples if used in	the s	study ⁷		
(g		Elements container Simple language Risks and discomforts Alternatives to partici Right to withdraw Benefits Purpose and procedur Others(Specify)	pation	ticipant Information Sh Data/ Sample sharing Need to recontact Confidentiality Storage of samples Return of research res Payment for participatio	C Ults	Statement that consider that consider that consider that stund that stunds of photograp	stud sent Ben dy ir hs/	y related injury is voluntary efit sharing volves research dentifying data		
8. P	۸ ۷	MENT/COMPENS/	ATION							
				d to participation and p	roceo	lures ⁸ ?				
(-	,	PI 🗆		Institution		oonsor	ager	cies 🛚 (s	pecify)	
(b)	-		eatment of research re		injuries?		Yes 🗆 N		\ □
(0						SAE? If yes, specify				
(0	,					et grant			10 LI IN/F	, _
(d	l)	-		-	-	ent till the relatedness is		— ermined for in	jury to the	е
(-	,	participants during	g the study	period? If yes, specify.			9.8	.P Yes □	No N/A	
(e	e)					during th e studyrpland to Ben	rlfDy		e & if lyl.o spit	tal

*Enclose undertaking from PI confirming the same Version 2.0

P.P.P.P

05

PRINCIPAL
M.R. Ambedkar Dental College & Hospital
Bengaluru - 560 005

9.	STORAGE AND CONFIDENTIALITY	
	(a) Identifying Information: Study Involves samples/data. If Yes, specify	Yes ☐ No ☐ NA ☐
	Anonymous/Unidentified \square Anonymized: Reversibly coded \square Irreversibly coded \square	☐ Identifiable ☐If
	identifiers must be retained, what additional precautions will be taken to ensure that ac	cess is limited /data is
	safeguarded? (e.g. data stored in a cabinet, password protected computer etc.)	
		(b)
	Who will be maintaining the data pertaining to the study?	` ,
	Where will the data be analyzed ⁹ and by whom?	
	(d) For how long will the data be stored?	
		es 🗆 No 🗖 Maybe 🗖
	If yes, explain how you might use stored material/data in the future?	
	OFOTION D. OTHER LOOLIES	
	SECTION D: OTHER ISSUES	
10	PUBLICATION, BENEFIT SHARING AND IPR ISSUES	
		Yes □ No □ NA □
	(a) Will the results of the study be reported and disseminated? If yes, specify.	
	(b) Will you inform participants about the results of the study?	Yes 🗆 No 🗆 NA 🗆
	(c) Are there any arrangements for continued provision of the intervention for participants, if	effective, once the
	study has finished? If yes describe in brief (Max 50 words)	Yes □ No □ NA □
	(d) Is there any plan for post research benefit sharing with participants? If yes, specify	Yes ☐ No ☐ NA ☐
	(e) Is there any commercial value or a plan to patent/IPR issues? If yes, please provide details	Yes ☐ No ☐ NA ☐
	(f) Do you have any additional information to add in support of the application, which is not i	
	the form? If yes, provide details.	Yes ☐ No ☐
	~ D 0	9
	p.k.,	- · · · · · · · · · · · · · · · · · · ·
	PRINC	

SECTION E: DECLARATION AND CHECKLIST 10

11. C	DECLARATION (Please tick as applicable)						
	I/We certify that the information provided in this application is complete and correct.						
	I/We confirm that all investigators have approved the submitted version of proposal/related documents.						
	I/We confirm that this study will be conducted in accordance with the latest ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants and other applicable regulations and guidelines.						
	I/We confirm that this study will be conducted in accordance with the Drugs and Cosmetics Act 1940 and its Rules 1945 as amended from time to time, GCP guidelines and other applicable regulations and guidelines.						
	I/We will comply with all policies and guidelines of the institute and affiliated/collaborating institutions where this study will be conducted.						
	I/We will ensure that personnel performing this study are qualified, appropriately trained and will adhere to the provisions of the EC approved protocol.						
	I/We declare that the expenditure in case of injury related to the study will be taken care of.						
	I/We confirm that an undertaking of what will be done with the leftover samples is provided, if applicable.						
	I/We confirm that we shall submit any protocol amendments, adverse events report, significant deviations from protocols, progress reports and a final report and also participate in any audit of the study if needed.						
	I/We confirm that we will maintain accurate and complete records of all aspects of the study.						
	I/We will protect the privacy of participants and assure confidentiality of data and biological samples.						
	I/We hereby declare that I/any of the investigators, researchers and/or close relative(s), have no conflict of interest (Financial/Non-Financial) with the sponsor(s) and outcome of study.						
	1/We have the following conflict of interest (PI/Co-I): 1						
	I/We declare/confirm that all necessary government approvals will be obtained as per requirements wherev-						
	er applicable.						
Siç	me of PI:dd mm yy me of Co-PI:						
	Signature: dd mm yy						
Na	me of Guide:						
Sig	gnature: dd mm yy						
Na	me of HOD:						
Sig	gnature:						

10 These formats are adaptable and can be modified by the Ethics Committee members depending on their needs and requirements

Acknowledgement for Receipt of Application (Copy to be provided to PI)


Bengaluru - Vērsan 25 07

12. CH	ECKLIST										
S. No	No Items						Yes	No	NA	Enclosure No	EC Remarks (If applicable)
ADMII	ADMINISTRATIVE REQUIREMENTS										(п аррисало)
1	Cover letter										
2	Brief CV of all Investigato	rs									
3	Good Clinical Practice (G	CP) t	rainin	g of investi	igators in	last 3 years					
4	Approval of scientific con	nmitte	ее								
5	EC clearance of other cen	iters*									
6	Agreement between colla	abora	ting pa	artners*							
7	MTA between collaboration	ng pa	rtners	*							
8	Insurance policy/certificat	te									
9	Evidence of external labo outsourced laboratory st					n externally					
10	Copy of contract or agreem	ent si	gned v	with the spo	onsor or d	onor agency					
11	Provide all significant possible negative decision or most authorities for proposed s and modification(s) to pr	odifie tudy	d pro (wheth	tocol) by	other E	Cs/Regulatory					
PROPO	OSAL RELATED									, ,	
12	Copy of the detailed proto	ocol ¹¹									
13	Investigators Brochure (If	appl	icable	for drug/b	oiological	s/device trials)					
14	Participant Information St Form (ICF)(English and to			and Partic	ipant Info	rmed Consent					
15	Assent form for minors (12	2-18 y	ears)	(English a	nd Trans	ated)					
16	Proforma/Questionnaire / Guides for Focused Group										
17	Advertisement/material to	o recr	uit pa	rticipants	(fliers, po	sters etc)					
PERMI	SSION FROM GOVERNI	NG A	UTHO	ORITIES							
	Other permissions	Req	uired	Not required	Receive	d Applied dd/ mm/yy				EC Remarks	
18	CTRI	[
19	DCGI	[
20	HMSC	[
21	NAC-SCRT	[
22	ICSCR	[
23	RCGM	[
24	24 GEAC										
25	BARC 🗆 🗆										
26	Tribal Board										
27	Others (Specify)]								
ANY O	THER RELEVANT INFOR	RMA	ΓΙΟΝ/	DOCUME	NTS RE	LATED TO TH	E STU	DY			
	Item YES NO NA Enclosure no									EC remarks	
28											
29										R.P.L	P

*For multicentre research.

MTA-Material transfer agreement; CTRI-Clinical Trial Registry-India; DCGI-Drug Controller General of India; HMSC- Health Ministry's Screening Committee;

MAC-SCRT- National Apex Committee for Stem Cell Research and Therapy; IC-SCR-Institutional committee for Stem Cell Research; RCGM- Review Committee on Genetic Manipulation; GEAC- Genetic Engineering Approval Committee; BARC- Bhabha Alomic Research Centre 10 Committee on Mational Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017, Section 4 Page no. 33 BOX 4.4(b) 108



M.R. Ambedkar Dental College & Hospital Bengaluru - 560 005

P.P.P.

(Annexure 1)

Logo of the

* In case this is first submission, leave it blank

Application Form for Expedited Review

		(Name of the Institution) EC Ref. No.* (For office use):	
Ti	tle o	f study:	
			Principal
ln	vesti	gator (Name, Designation and Affiliation):	
1.	Cho	ose reasons why expedited review from EC is requested 12?	
	i.	Involves non-identifiable specimen and human tissue from sources like blood banks, tissue banks and	
		left-over clinical samples.	_
	ii. :::	Involves clinical documentation materials that are non-identifiable (data, documents, records).	
	iii.	Modification or amendment to approved protocol (administrative changes/correction of typographica errors and change in researcher(s)).	
	iv.	Revised proposal previously approved through expedited review, full review or continuing review of	
		approved proposal.	
	٧.	Minor deviation from originally approved research causing no risk or minimal risk.	
	vi.	Progress/annual report where there is no additional risk, for example activity limited to data analysis.	
		Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee.	_
	vii.	For multicentre research where a designated EC has approved the proposal, a participating EC may	
		review participating centre specific information and modifications in the study proposal through furnities meeting/expedited review depending on the importance of local consent related issues in	
		specific to the centre.	voiveu
	viii.	Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017).	
	ix.	Any other (please specify)	
2.	ls w	aiver of consent being requested?	□ No □
3.		_	□ No □
		es give details:	
	••••		
	Sigr	nature of PI:dd mr	m yy
	Con	nments of EC Secretariat:	
	<u> </u>	O.P.P	n vv
	_	nature of Member Secretary:	уу
¹² Ri ¹³ Fo	efer to r detai	National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.21 College & Fils, refer to application for initial review, Section-C, 5(b)	lospital

Bengaluru - 560 005 Version 2.0

(Annexure 2)

Application Form for Exemption from Review

	(Name of the Institution) EC Ref. No. (For office use):	
	Title of study:	
	Investigator (Name, Designation and Affiliation):	
1.	. Choose reasons why exemption from ethics review is requested 14?	
	i. Research on data in the public domain/ systematic reviews or meta-analyses]
	ii. Observation of public behavior, information recorded without limited identifiers and disclosure	3
	would not harm the interests of the observed person	7
	iii. Quality control and quality assurance addits in the institution	_
	iv. Comparison among instructional techniques, curricula, or classroom management methods	
	v. Consumer acceptance studies related to taste and food quality	_ ,
	vi. Public health programmes by government agencies ¹⁵ vii. Any other (please specify in 100 words):	_
	Signature of PI:	mm yy
	Comments of EC Secretariat:	
	Signature of Member Secretary:	mm yy

¹⁴Select the category that applies best to your study and justify why you feel it should be exempted from review. For a detailed understanding of the type of studies that are exempt from review, refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2.

¹able 4.2.

15 Such as programme evaluation where the sole purpose of the exercise is refinement and improvement of the programme or monitoring (where there are no individual identifiers)

(Annexure 3)

Continuing Review / Annual report format

	Institute
	(Name of the Institution) EC Ref. No. (For office use):
	Title of study:
	Investigator (Name, Designation and Affiliation):
	Date of EC Approval: dd mm yy
3.	Period of Continuing Report: dd mm yy to dd mm yy Does the study involve recruitment of participants? Yes No
	(a) If yes, Total number expected
	(b) Enrolment status - ongoing / completed/ stopped (c) Report of DSMB¹6 Yes □ No □ NA□ (d) Any other remark
	(e) Have any participants withdrawn from this study since the last approval? Yes □ No □ NA□ If yes, total number withdrawn and reasons:
4.	Is the study likely to extend beyond the stated period ? ¹⁷ Yes No I If yes, please provide reasons for the extension.
5.	Have there been any amendments in the research protocol/Informed Consent Document (ICD) during the past approval period?
	If No, skip to item no. 6 (a) If yes, date of approval for protocol and ICD: Yes No No
	(b) In case of amendments in the research protocol/ICD, was re-consent sought from participants? Yes ☐ No☐ If yes, when / how:
	P.R.P.
	PRINCIPAL M.R. Ambedkar Dental College & Hospital

stı	any new information available that changes the benefit - risk analysis of human participant udy? yes, discuss in detail:	Yes ☐ No ☐
7. Hav	ve any ethical concerns occurred during this period? yes, give details:	Yes No No
	Have any adverse events been noted since the last review? Describe in brief:	Yes No No
(b)	Have any SAE's occurred since last review? If yes, number of SAE's : Type of SAE's:	Yes □ No □
(c)	Is the SAE related to the study? Have you reported the SAE to EC? If no, state reasons	Yes □ No □ Yes □ No □
	s there been any protocol deviations/violations that occurred during this period? yes, number of deviations	
На	ave you reported the deviations to EC? If no, state reasons	Yes □ No □
10. In	case of multicenteric trials, have reports of off-site SAEs been submitted to the EC?	Yes □ No □ NA □
11. Are	e there any publications or presentations during this period? If yes give details	Yes □ No □
Ar	ny other comments:	
Si	gnature of PI:	dd mm yy

P.P.P.

(Annexure 4) Application/Notification form for Amendments (Name of the Institution) **EC Ref. No.** (For office use): Title of study: Principal Principal Investigator (Name, Designation and Affiliation): 1. Date of EC approval: dd mm yy Date of start of study 2. Details of amendment(s) Location in the S.No **Existing Provision Proposed Amendment** Reason protocol/ICD 18 Yes ☐ No☐ 3. Impact on benefit-risk analysis If yes, describe in brief: Yes □ No□ 4. Is any reconsent necessary? Yes ☐ No☐ If yes, have necessary changes been made in the informed consent? 5. Type of review requested for amendment: Expedited review (No alteration in risk to participants) Full review by EC (There is an increased alteration in the risk to participants) 6. Version number of amended Protocol/Investigator's brochure/ICD:

P.R.P.

PRINCIPAL

M.R. Ambedkar Dental College & Hospital Bengaluru - 560 005

Signature of PI:

(Annexure 5) Protocol Violation/Deviation Reporting Form (Reporting by case) (Name of the Institution) **EC Ref. No.** (For office use): Title of study: Principal Investigator (Name, Designation and Affiliation): 1. Date of EC approval Date of start of study dd 3. Total number of deviations /violations reported till date in the study: 4. Deviation/Violation identified by: Principal Investigator/study team Sponsor/Monitor SAE Sub Committee/EC 5. Is the deviation related to (Tick the appropriate box): Consenting Source documentation Staff Enrollment Participant non-compliance Laboratory assessment **Investigational Product** Others (specify) Safety Reporting

6. Provide details of Deviation/Violation:

7. Corrective action taken by PI/Co-I:

PRINCIPAL

(Annexure 6) Serious Adverse Event Reporting Format (Biomedical Health Research)

(Na	me of the Institution)	EC Ref. No. (For office use):
Title of study:		
		Principa
Investigator (Name, Designation and Affiliation):		
Participant details :		
Initials and ID Age at the time of event	Gender	Weight:(Kgs)
	Male ☐ Female ☐	Height:(cms)
Suspected SAE diagnosis:		
Date of onset of SAE: dd mm yy	Describe the event 19:	
Date of reporting SAE:		
Details of suspected intervention causing SAE 20		
Report type: Initial □ Follow-up □ Final □		
	mm yy	
Have any similar SAE occurred previously in this study?	If yes, please provide detail	ls. Yes □ No□
		200
uration setting site signs symptoms severity criteria for regarding the		P.R.P

²⁰Refers to research intervention including basic, applied and operational research or clinical research, except for investigational new drugs. If it is all all academic clinical trial, mention name, indications, dosage, form and strength of the drug(s) Bengaluru - 560 005 Version 2.0

7.	In case of a multi-centric study, have any of the other study sites reported similar SAEs? (Please list number of cases with details if available)							
8.	Tick whichever is applic	cable 1	for the SAE: (Kindly note	that	this refers to the Inter	ventic	on being evaluated and	TON b
	disease process)							
	A. Expected event \square	Une	expected event \square					
	B.							
	Hospitalization		Increased Hospital Stay		Death		Congenital anomaly/birth defect	
	Persistent or significant disability/incapacity		Event requiring intervention (surgical or medical) to prevent SAE		Event which poses threat to life		Others	
		•	bbable cause of death		<u></u>			
	Permanent/significal	nt fun	ctional/cosmetic impairm	nent				
	Not Applicable							
9.		nanag	ement provided for adve	rse r	eaction (if any) to the	resea	rch participant. (Includ	de infor-
	mation on who paid, he	ow mı	uch was paid and to who	om).				
10	Provide details of comp	ensat	tion provided / to be prov	vided	to participants (Includ	de inf	ormation on who pays	 , how
	much, and to whom).							
11	Outcome of SAE							
	Fatal U				covered \square			
	Continuing Recovering				known \square			
	Recovering \square			Oti	ner (specify) L			
12	Provide any other relev	ant inf	formation that can facilita	ate as	sessment of the case	such	as medical history	
13	Provide details about Pl	's fina	I assessment of SAE rela	atedn	ess to research.			
							p.R.P.1 P	
							PRINGIPAL	
	Signature of PI				Ad R Amala	edka	r Dental College & H	
	Signature of 1.1				·····	Ben	galuru - 560 005 V	ersion 2.

(Annexure 7)

	Institute Institute Institute
	(Name of the Institution) EC Ref. No. (For office use):
	Title of study:
	Investigator (Name, Designation and Affiliation):
	Date of EC approval: dd mm yy Date of start of study:
	Date of last progress report submitted to EC: dd mm yy Date of termination/suspension/discontinuation:
<i>,</i> .	dd mm yy
Į.	Tick the appropriate
	Premature Termination ☐ Suspension ☐ Discontinuation ☐
	Reason for Termination/Suspension/Discontinuation:
	Action taken post Termination/ Suspension/Discontinuation (if any):
5.	Plans for post study follow up/withdrawal ²¹ (if any):
3.	Details of study participants:
	Total participants to be recruited: Screened: Screen failures:
	Enrolled: Reason (Give details):
	Withdrawn by PI:
	M.R. Ambedkar Dental College & Hospital

	Active on treatment:	Completed treatment :	Participants on follow-	up:
	Participants lost to follow up:	Any other:	Number of drop ou	ıts:
	Reasons for each drop-out:			
7.	Total number of SAEs reported till			
	Have any unexpected adverse ever	nts or outcomes observed in the	e study been reported to the EC?	Yes □ No□
8.	Have there been participant compl	aints or feedback about the stu	udy?	Yes ☐ No☐
	If yes, provide details:			
9.	Have there been any suggestions f			Yes ☐ No☐
	If yes, have you implemented that	suggestion?		Yes ☐ No☐
10	Do the procedures for withdrawal o	of enrolled participants take into	o account their rights and welfare	? Yes ☐ No☐
	(e.g., making arrangements for me	dical care of research participa	ants): If Yes, provide details	
	Summary of results (if any):			
Si	gnature of PI:		dd mm (.R.V	P

	Application	on Form for Clinic	cal Trials	
Logo of the Institute	(Nam	ne of the Institution)	EC Ref. No. (For office use).	
Title of study:				
Investigator (Name, Designation and				
. Type of clinical trial Regulatory	r trial \square	Academic trial		
CTRI registration number: NAB			EC registration number:	
_			Lo registration number	•••••
2. If regulatory trial, provide status of CDS	SCO permiss			
Approved and letter attached		Applied, under prod	ess ⊔	
Not applied (State reason)				
3. Tick all categories that apply to your tr	ial _		_	
Phase - I		Phase II		
Phase III	빌		arketing Surveillance	
Investigational medicinal products		Investigational New		
Medical devices		New innovative pro	_	
Drug/device combination		Bioavailability/Bioe	<u></u>	
Non-drug intervention		Repurposing an ex	<u> </u>	
Indian system of medicine (AYUSH)		Stem cells		
Phytopharmaceutical drug		Approved drug for	any new indication	
Others (specify)		or new route of adr		
Trial design of the study				
I. Randomized		Factorial		
Non randomized		Stratified		
Parallel		Adaptive		
Cross-over		Comparison trial		
Cluster		Superiority trial		
Matched-pair		Non-inferiority trial		
Others (specify)	Ц	Equivalence trial	Ц	
II. If there is randomization, how will the	e participants	s be allocated to the co	ntrol and study group(s)?	
III. Describe the method of allocation c	oncealment ((blinding / masking), if a	applicable. P.P.P	
			Ambedkar Dental College	

_	, ,	ite Management Organisation (SMO) / Any	
as public relation/human resourc			Yes ☐ No ☐
If yes, Name and Contact de	etails:		
State how the CRO/SMO/agend	cy will be involved	in the conduct of the trial (tick all that app	oly)
Project management		Clinical and medical monitoring	
Regulatory affairs		Data management	
Statistical support		Medical writing	
Site management		Audits, quality control, quality assurar	nce 🗆
Finance management		Recruitment and training	
Administrative support		Others (specify)	
		regulatory approval details.	
II. Already approved drugs or a	a combination of two		ange in dosage for
	a combination of two		
II. Already approved drugs or a route of administration. If yes	a combination of two		ange in dosage for Yes □ No □ NA
II. Already approved drugs or a route of administration. If yes	o prepared and /or	o or more drugs with new indications / ch	ange in dosage for Yes □ No □ NA
II. Already approved drugs or a route of administration. If yes	o prepared and /or me drug/s, device/s	o or more drugs with new indications / ch	ange in dosage for Yes □ No □ NA d biologics. Yes □ No □ NA
II. Already approved drugs or a route of administration. If yes	o prepared and /or me drug/s, device/s	o or more drugs with new indications / ch	ange in dosage for Yes □ No □ NA d biologics. Yes □ No □ NA
II. Already approved drugs or a route of administration. If yes	o prepared and /or ne drug/s, device/s ory work or site prepareds)	o or more drugs with new indications / ch	ange in dosage for Yes No No No

9.	Is there an initial screening/ use of existing database for participant selection?	Yes ☐ No ☐ NA ☐
	If Yes, provide details ²²	
10.	Is there any anticipated incidence, frequency and duration of adverse events related to the in	ntervention?
	If yes, provide details of arrangements made to address them.	Yes ☐ No ☐ NA ☐
11.	Does the study use a placebo?	
	If yes, justify the use of the placebo and risks entailed to participants.	Yes 🗆 No 🗆 NA 🗆
12.	Will current standard of care be provided to the control arm in the study?	Yes 🗆 No 🗆 NA 🗖
	If no, please justify.	
13.	Are there any plans to withdraw standard therapy during the study? If yes, please justify.	Yes ☐ No ☐ NA ☐
14.	Are there any rules to stop the protocol in case of any adverse events? If yes, please specify.	Yes ☐ No ☐ NA ☐
15.	Does the study have a Data and Safety Monitoring Plan? If no, please justify.	Yes □ No □
	p.R.f	ا ا

PRINCIPAL

Version 2.0

²² In order to select participants for your protool does the protocol require you to screen an initial population of lefer to an existing participants. If yes, provide details on the same Bengaluru - 560 005

16.	Participant Inform	mation	Sheet(PIS) and Informed Consent Form (ICF)		
	English Other(Specify)		Local language	ation of the English version	on and
		-	which translations were done		
	Justify if transla	ition n	ot done		
17.	Involvement/con	sultatio	on of statistician in the study design	Y	es 🗆 No 🗆 NA 🗆
18.	Is there any insu	rance	coverage of the trial? If yes, provide details.		Yes 🗆 No 🗆
			vith Medical Council of India (MCI) or the State Me	dical Council registration	? Yes □ No □
	Please provide		S.		Yes LI NO LI
	II. Is the PI traine	d in G0	CP in last 3 years? If yes, Please enclose certificate	e Y	es □ No □
	Signature of	PI:		dd mm yy	
				P.R.P	— p
				b.k	•

PRINCIPAL

M.R. Ambedkar Dental College & Hospital
Bengaluru - 560 005

(Annexure 9)

Serious Adverse Event Reporting Format (Clinical trials)

	Logo of the Institute
	(Name of the Institution) EC Ref. No. (For office use):
	Title of study:
	Investigator (Name, Designation and Affiliation):
1.	Participant details :
	Initials and Case No./ Age at the time of event Gender Weight:(Kgs)
	Subject ID Male Height: (cms)
	Female \square
2.	Report type: Initial Follow-up Final Final
	If Follow-up report, state date of Initial report dd mm yy
	What was the assessment of relatedness to the trial in the initial report?
	By PI - Related ☐ By Sponsor - Related ☐ By EC - Related ☐
	Unrelated ☐ Unrelated ☐ Unrelated ☐
3.	Describe the event and specify suspected SAE diagnosis:
1	Date of onset of SAE: dd mm yy Date of reporting: dd mm yy
	Onset lag time after administration of intervention: Location of SAE (Clinic/Ward/Home/Other)
6.	Details of suspected study drug/device/investigational procedure causing SAE:
	Suspect study drug (include generic name) device/intervention:
	II. Indication(s) for which suspect study drug was prescribed or tested:
	III. Route(s) of administration, daily dose and regimen, dosage form and strength :
	IV. Therapy start date: dd mm yy Stop date: dd mm
7.	Was study intervention discontinued due to event? PRINCIPATES No M.R. Ambedicar Deptal College & Hospital

8.	Did the reaction decline after stopping or reducing the dosage of the study drug / procedure? Yes \Box No \Box							
	If ye	es, provide details about the reduced dose	ə					
9.	Did	I the reaction reappear after reintrodu	cing the stu	idy drug / procedure?	Yes ☐ No ☐ NA ☐			
	If y	es, provide details about the dose						
10	Со	ncomitant drugs history and lab invest	tigations:					
	I.	Concomitant drug (s) and date of add	ministration	dd mm yy				
	II.	Relevant test/laboratory data with da	ites:	dd mm yy				
	III.	Patient relevant history including pre-ealcohol use, hepatic/ renal dysfunction	existing medi	ical conditions (e.g. allergies, race, pre	gnancy, smoking,			
11.	.Ha\	ve any similar SAE occurred previously	y in this stud	ly? If yes, please provide details.	Yes ☐ No ☐			
12		riousness of the SAE:						
	De	ath		Congenitial anomaly				
	Life	e threatening		Required intervention to prevent				
		spitalization-initial or prolonged		permanent impairment / damage				
		sability		Others (specify)				
13		scribe the medical management provi		erse reaction (if any) to the research pa	articipant. (Include infor-			
14	Ou	tcome of SAE:						
	Fat	tal		Recovered				
	Со	ntinuing		Unknown				
	Re	covering		Other (specify)				
		s the research participant continued covide details about Pl's final assessme			Yes □ No □ NA □			
17.		s this information been communicated	to sponsor/	CRO/regulatory agencies?				
10		· ·		012	Yes □ No □			
	. Does this report require any alteration in trial protocol? Provide details of compensation provided / to be provided the participants (Include information on who pays, how much, and to whom)							
		, , , , , , , , , , , , , , , , , , ,			Polip			
				b.k.	,, ,			
	Sig	nature of PI:		M.R. Ambedkar Den	Ital College & Hospital			

Logo of the

(Annexure 10) Application Form for Human Genetics Testing Research

	Institute (Name of the Institution) EC Ref. No. (For office use):
	Title of study:
	Investigator (Name, Designation and Affiliation):
1.	Describe the nature of genetic testing research being conducted.
	(e.g screening/gene therapy/newer technologies/human embryos/foetal autopsy)
2.	Does the study involve pretest and post-test counselling? If yes, please describe. Yes ☐ No ☐ NA ☐
3.	Explain the additional safeguards provided to maintain confidentiality of data generated.
4.	If there is a need to share the participants' information/investigations with family/community, is it addressed in the informed consent? Yes \(\subseteq \text{No} \subseteq \text{NA} \subseteq \) If findings are to be disclosed, describe the disclosure procedures (e.g. genetic counseling)
5.	Is there involvement of secondary participants? Yes No NA If yes, will informed consent be obtained? State reasons if not. Yes No NA
6.	What measures are taken to minimize/mitigate/eliminate conflict of interest?
7.	Is there a plan for future use of stored samples for research? If yes, has this been addressed in the informed consent? Signature of PI: M.R. Ambedkar Denial College & Hospital Bengaluru - 560 005 Version 2.0

(Annexure 11)

Logo of the Institute	Applic	ation Form for Socio-Be	navioural a	nd Public Healti	1 Kesearch
		(Name of th	ne Institution)	EC Ref. No. (For office use):
Title of stud	dy:				
					Principal
Investigator	(Name, Designa	ation and Affiliation):			
l. Data collection	on method used	in the study			
Focus group		Questionnaire/Survey	Ob	servation	
Interviews		Documents and records	☐ Eth	nographies/Oral	
Others (Speci	ify)		his	tory/Case studies	
If it is an inte		be audio-video recording of	participants' in	iterview? If yes, jus	tify the reasons and Yes □ No □
2. Type of inforundation Individual co		Gate-keeper consent		mmunity consent	
	Others \square (specify) Provide details of safeguards to ensure privacy and confidentiality of participants in the event of data sharing.				
Describe stra	Describe strategies to manage if any patterns of behaviour of self-harm or harm to the society are identified.(e.g.				
Suicide or in	fanticide)				Yes ☐ No ☐ NA ☐
Are cultural r	norms/Social cor	nsiderations/Sensitivities take	en into accoun	t while designing th	ne study and
participant re					Yes □ No □
S. Is there a use	e of an interprete	er? If yes, describe the selecti	on process.		Yes ☐ No ☐ NA ☐
				p.P.	PIP
				PRI	NCIPAL ntal College & Hospital

Bengaluru - 560 005 Version 2.0

7.	Describe any preparatory work or site preparedness for the study	Yes 🗆 No 🗖 NA 🗖
8.	I. Type of risk related to procedures involved in the study Invasive □ Potentially harmful □ Emotionally disturbing □ Involving disclosure Describe the risk minimization strategies.	osure \square
	II. Justify reasons if individual harm is overriding societal benefit.	/es □ No □ NA □
	III. Describe how do societal benefits outweigh individual harm.	
9.	Does the study use incomplete disclosure or active deception or authorized deception? If yes, pro-	ovide details and
10.	Describe the debriefing process that will be used to make participants aware of the incomplete d deception, including their right to withdraw any record of their participation.	
	Signature of PI:	yy Hospital

(Annexure 12)

	Logo of the Institute Study completion/Final report format
	(Name of the Institution) EC Ref. No. (For office use):
	Title of study:
	Investigator (Name, Designation and Affiliation):
1.	Date of EC approval: dd mm yy
 3. 	Date of start of study: dd mm yy Date of study completion: dd mm yy Provide details of:
	a) Total number of study participants approved by the EC for recruitment:
	b) Total number of study participants recruited:
	c) Total number of participants withdrawn from the study (if any):
4.	Describe in brief the publication/ presentation/dissemination plans of the study findings. (Also, mention if both positive and negative results will be shared)
5.	Describe the main ethical issues encountered in the study (if any)
6.	State the number (if any) of Deviations/Violations/ Amendments made to the study protocol during the study period Deviations: Amendments:
7.	Describe in brief plans for archival of records / record retention:
	P.P.P
	PRINCIPAL M.R. Ambedkar Dental College & Hospital

 23 Explanation for the withdrawal of participants whether by self or by the PI

Bengaluru - 560 005

8. Is there a plan for post study follow-up?	Yes ☐ No☐
If yes, describe in brief:	
9. Do you have plans for ensuring that the data from the study can be shared/ accessed easily?	Yes □ No□
If yes, describe in brief:	
10.1s there a plan for post study benefit sharing with the study participants?	Yes □ No□
If yes, describe in brief:	
11. Describe results (summary) with Conclusion 24 :	
12. Number of SAEs that occurred in the study:	
13. Have all SAEs been intimated to the EC?	Yes □ No□
13. Have all SALS been intilinated to the LC :	163 L 110L
14. Is medical management or compensation for SAE provided to the participants?	Yes ☐ No☐
If yes, provide details	
P.E.P	م
	al College & Hospital

(Annexure 13)

Qualifications:

Format for Curriculum Vitae for Investigators

	(Name of the	Institution) EC	Ref. No. (For office use):
Name:			
Present affilia	tion (Job title, department, and organisation):		
Address (Full	work address):		

Email address: Telephone number:

Professional registration (Name of body, registration number and date of registration):

Previous and other affiliations (Include previous affiliations in the last 5 years and other current affiliations):

Projects undertaken in the last 5 years:

P.R.P.

Relevant research training/experience in the	area ²⁵ :	
Relevant publications (Give references to all r	elevant publications in the last five years):	
Signature	Date:	
Signature	Date.	

P.R.P.

²⁵ Details of any relevant training in the design or conduct of research, for example in the Ethics Training, Human participants protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to participants protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to participants protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to protect the consent of the Cons